Results 41 to 50 of about 10,401 (200)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation

Respiratory Medicine Case Reports, 2023
Eosinophilic granulomatosis with polyangiitis (EGPA) is systemic vasculitis caused by eosinophilia affecting small to medium-sized blood vessels, which damages the organs.
Mari Sato, Masakiyo Yatomi, Ikuo Wakamatsu, Shogo Uno, Chiharu Hanazato, Tomomi Masuda, Koichi Yamaguchi, Haruka Aoki-Saito, Norimitsu Kasahara, Yosuke Miura, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Noriaki Sunaga, Takuhisa Okada, Hayato Ikota, Takeshi Hisada, Toshitaka Maeno   +17 more
doaj   +1 more source

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources

Anaphylaxis to three humanized antibodies for severe asthma: a case study

Allergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi   +9 more
doaj   +1 more source

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine, 2023
BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage.
Florence Roufosse, Joseph Butterfield, Jonathan Steinfeld, Jane H. Bentley, Robyn von Maltzahn, Namhee Kwon, Linda Nelsen   +6 more
doaj   +1 more source

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

BMC Pulmonary Medicine, 2019
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance ...
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Frontiers in Immunology, 2022
BackgroundCurrent standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive/cytotoxic (IS/CT) therapies.
Andreas Reiter, Guillaume Lefevre, Maria C. Cid, Namhee Kwon, Eleni Mavropolou, Steven W. Yancey, Jonathan Steinfeld   +6 more
doaj   +1 more source

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]

, 2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy, Buhl, Roland, Canvin, Janice, Sun, Shawn X, Weiss, Sivan   +4 more
core   +3 more sources

Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis

International Forum of Allergy &Rhinology, EarlyView.
Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Eric R. Ramos, Sriram Satyavolu, Ashley L. Miller, George A. Scangas, Zachary M. Soler, Rodney J. Schlosser, Yufan Lin, Vinay K. Rathi   +7 more
wiley   +1 more source

Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

ERJ Open Research
Background The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced oral corticosteroid (OCS) use compared with placebo in patients with relapsing or ...
David R.W. Jayne, Benjamin Terrier, Bernhard Hellmich, Paneez Khoury, Lee Baylis, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Michael E. Wechsler, Praveen Akuthota   +10 more
doaj   +1 more source

Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions [PDF]

, 2018
Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical manifestations and treatment modalities. The disorders are suspected to result from an abnormal inflammatory response to allergen(s), and individuals may ...
Gupta, Sandeep K., Naramore, Sara
core   +1 more source